Given the role of IL-6 in the activation of androgen receptors, neuroendocrine differentiation and angiogenesis in prostate cancer development, attempts have been made to inhibit the cytokine signalling pathways using monoclonal antibodies [67]. Here, IL6 is linked to prostate cancer.